ArticleAmerican journal of human genetics2026
Multiple-testing corrections in case-control studies using identity-by-descent segments.
Article in American journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HiFiMAP: High-resolution fast identity-by-descent mapping test.medRxiv : the preprint server for health sciences · 2026Article
- Multiple-testing corrections in selection scans using identity-by-descent segments.American journal of human genetics · 2025Article
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
Identity-by-descent (IBD) mapping provides complementary signals to genome-wide association studies (GWASs) when multiple causal haplotypes or variants are present but not directly tested. We propose the difference between affected-affected and control-control IBD rates as an IBD mapping statistic. For our hypothesis test, we use a computationally efficient approach from the stochastic processes literature to derive genome-wide significance levels that control the family-wise error rate (FWER). Whole-genome simulations indicate that our method conservatively controls the FWER. We pair our IBD mapping approach with a selection scan and a validation procedure via phenotype randomization so that one can contrast results for evidence of confounding due to positive selection, sequencing artifacts, or population structure. We developed automated and reproducible workflows to phase haplotypes, call local ancestry probabilities, and perform the IBD mapping scan, the former two tasks being important preprocessing steps for haplotype analyses. We applied our methods to search for Alzheimer disease (AD) risk loci in the Alzheimer's Disease Sequencing Project (ADSP) genome data. We identified six genome-wide significant signals of AD risk among samples genetically similar to African and European reference populations and self-identified Amish samples. Some variants in the six risk loci we detected have previously been associated with AD, dementia, and memory decline, and four genes at two of these loci have already been nominated as therapeutic targets for AD. Overall, our scalable approach makes further use of large consortia resources, which are expensive to collect but provide insights into disease mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.